Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Touts Expanded Product Lineup as it Wraps up ParAllele Acquisition

NEW YORK, Oct. 24 (GenomeWeb News) - As GenomeWeb News reported earlier today, Affymetrix confirmed today that it has closed the acquisition of privately held ParAllele BioScience in a stock-and-cash transaction worth around $121 million.

 

Affymetrix said in a statement that ParAllele stockholders approved the acquisition on Oct. 20, and that it was completed on Oct. 21.

 

ParAllele stockholders will receive around $120.8 million in the form of $11.7 million in cash and around 2.29 million shares of Affymetrix common stock.

 

Stephen Fodor, founder and CEO of Affymetrix, said in a conference call following the company's third-quarter earnings last Thursday that he expects "a quick and successful integration of companies" in the wake of the acquisition.

 

Affymetrix "will launch a series of innovative new products, including a product covering 20K coding DNA SNPs, several disease-specific SNP panels including inflammation and cancer, and an expanding range of custom SNP panels spanning 1,500 to 20,000 SNPs," Fodor said.

 

Affymetrix said in a statement that it will add 1,500 new SNP custom assays and 20,000 non-synonymous coding SNP assays to its product portfolio as a result of the acquisition.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.